Shiraz University of Medical Sciences & Health Services, Shiraz, Iran.
Indian J Med Res. 2010 May;131:670-4.
BACKGROUND & OBJECTIVES: The aim of this study was to compare the effects of bromocriptine versus cabergoline on pregnancy in hyperprolactinaemic infertile women.
A total of 183 infertile women with hyperprolactinemia undergoing intrauterine insemination (IUI) were randomly divided into two groups. Group A: 94 with bromocriptine and group B:89 with cabergoline. The efficacy and safety was evaluated on the basis of normalization of prolactin levels, normalization of menstrual cycle, disappearance of galactorrhea, occurrence of pregnancy and adverse effects with each of these medications.
The presence of galactorrhea and irregular menstruation were significantly lower in patients of group B than group A (P<0.001 and P=0.011, respectively) with a significant lower prevalence of side effects in cabergoline group. Pregnancy was significantly more achieved among the women with the treatment of cabergoline (82%) as compared to bromocriptine (56.4%) (P<0.001).
INTERPRETATION & CONCLUSION: Our results suggest that cabergoline treatment in infertile women with prolactinemia is more effective. It lowers prolactin with better tolerability and much more effective in the achievement of pregnancy.
本研究旨在比较溴隐亭与卡麦角林对高泌乳素血症性不孕妇女妊娠的影响。
183 例高泌乳素血症接受宫腔内人工授精（IUI）的不孕妇女被随机分为两组。A 组：94 例溴隐亭；B 组：89 例卡麦角林。根据泌乳素水平正常化、月经周期正常化、泌乳消失、妊娠发生和每种药物的不良反应评估疗效和安全性。
B 组患者的泌乳和月经不规律发生率明显低于 A 组（P<0.001 和 P=0.011），卡麦角林组的不良反应发生率明显较低。卡麦角林组（82%）的妊娠率明显高于溴隐亭组（56.4%）（P<0.001）。
我们的结果表明，卡麦角林治疗泌乳素血症不孕妇女更有效。它能降低泌乳素，具有更好的耐受性，更有效地实现妊娠。
